Market Closed -
Nasdaq
01:30:00 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
4.53
USD
|
+1.80%
|
|
-12.72%
|
-68.80%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
216.4
|
247.8
|
518.4
|
160
|
-
|
-
|
Enterprise Value (EV)
1 |
216.4
|
247.8
|
518.4
|
160
|
160
|
160
|
P/E ratio
|
-4.28
x
|
-3.01
x
|
-4.22
x
|
-1.09
x
|
-1.29
x
|
-1.22
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
74.6
x
|
50.9
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
74.6
x
|
50.9
x
|
EV / EBITDA
|
-
|
-2.99
x
|
-4.16
x
|
-1
x
|
-0.89
x
|
-0.77
x
|
EV / FCF
|
-5.6
x
|
-3.91
x
|
-
|
-1.19
x
|
-1.09
x
|
-1.02
x
|
FCF Yield
|
-17.8%
|
-25.6%
|
-
|
-83.8%
|
-91.6%
|
-98.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
29,045
|
29,396
|
35,706
|
35,945
|
-
|
-
|
Reference price
2 |
7.450
|
8.430
|
14.52
|
4.450
|
4.450
|
4.450
|
Announcement Date
|
28/02/22
|
28/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
2.143
|
3.143
|
EBITDA
1 |
-
|
-
|
-82.94
|
-124.6
|
-160.3
|
-179
|
-208.4
|
EBIT
1 |
-
|
-41.67
|
-83.63
|
-126.1
|
-159.3
|
-165.8
|
-189.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-7,735.17%
|
-6,031.97%
|
Earnings before Tax (EBT)
1 |
-
|
-41.57
|
-81.83
|
-117.3
|
-154.6
|
-163
|
-188.6
|
Net income
1 |
-5.324
|
-41.57
|
-81.83
|
-117.3
|
-154.3
|
-163.6
|
-188.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-7,633.84%
|
-5,985.16%
|
EPS
2 |
-0.5000
|
-1.740
|
-2.800
|
-3.440
|
-4.087
|
-3.439
|
-3.641
|
Free Cash Flow
1 |
-
|
-38.61
|
-63.45
|
-
|
-134
|
-146.5
|
-157
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-6,836.66%
|
-4,995.45%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/04/21
|
28/02/22
|
28/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-17.3
|
-23.31
|
-26.1
|
-29.74
|
-27.27
|
-30.7
|
-36.91
|
-
|
-40.7
|
-39.73
|
-38.95
|
-
|
-
|
EBIT
1 |
-14.74
|
-16.4
|
-17.47
|
-23.48
|
-26.28
|
-30.03
|
-27.66
|
-31.12
|
-37.33
|
-37.33
|
-40.58
|
-39.34
|
-38.47
|
-40
|
-41.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14.71
|
-16.37
|
-17.26
|
-22.89
|
-25.31
|
-29.05
|
-24.89
|
-28.43
|
-34.88
|
-34.88
|
-38.8
|
-38.48
|
-38.06
|
-40
|
-41.5
|
Net income
1 |
-14.71
|
-16.37
|
-17.26
|
-22.89
|
-25.31
|
-29.05
|
-24.89
|
-28.43
|
-34.88
|
-34.88
|
-38.68
|
-38.27
|
-38.16
|
-40
|
-41.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5100
|
-0.5600
|
-0.5900
|
-0.7800
|
-0.8600
|
-0.9800
|
-0.7000
|
-0.8000
|
-0.9800
|
-0.9800
|
-1.071
|
-1.026
|
-0.9709
|
-1.090
|
-1.130
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/22
|
16/05/22
|
01/08/22
|
07/11/22
|
28/03/23
|
02/05/23
|
31/07/23
|
30/10/23
|
28/03/24
|
01/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-38.6
|
-63.4
|
-
|
-134
|
-147
|
-157
|
ROE (net income / shareholders' equity)
|
-
|
-45.2%
|
-57%
|
-
|
-85.6%
|
-79%
|
-91.3%
|
ROA (Net income/ Total Assets)
|
-
|
-33.5%
|
-52%
|
-
|
-74.1%
|
-76%
|
-73.6%
|
Assets
1 |
-
|
124.1
|
157.5
|
-
|
208.3
|
215.2
|
255.6
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
3.17
|
1.03
|
-
|
2.32
|
3.3
|
3.35
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
154%
|
106.59%
|
Announcement Date
|
12/04/21
|
28/02/22
|
28/03/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
4.45
USD Average target price
24.43
USD Spread / Average Target +448.96% Consensus |
1st Jan change
|
Capi.
|
---|
| -68.80% | 160M | | +21.85% | 46.93B | | +37.63% | 39.08B | | -8.05% | 38.48B | | +29.04% | 31.01B | | -13.75% | 26.14B | | +10.65% | 25.88B | | +38.43% | 12.53B | | -6.92% | 11.36B | | -12.29% | 10.65B |
Other Biotechnology & Medical Research
|